Open Access Open Access  Restricted Access Subscription or Fee Access

Epigenetic Regulation and Plasticity in Human Diseases

Preeti Rawat

Abstract


In normal human development as well as in the case of diseased development, epigenetic changes are involved. The role of plasticity is important and directed on the understanding feature of epithelial cell biology, and maybe a significant pathway for disease pathobiology and pathogenesis. During embryonic development, an epigenetic mechanism is important for the growth and development of genetically identical cells that are obtained from different outcomes. In this review study, the author has tried to focus on the function of epigenetic factors in stem cells and increase the understanding of epigenetic disease mechanisms.


Full Text:

PDF

References


Van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. Ann. NY Acad. Sci. 2002; 981: 61–81.

Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007; 447(7143): 433–440.

Bird A. Perceptions of epigenetics. Nature. 2007; 447(7143): 396–398.

Bestor TH. DNA methylation: evolution of a bacterial immune function into a regulator of gene expression and genome structure in higher eukaryotes. Philosophical Transactions of the Royal Society of London B. Biological Sciences. 1990; 326(1235): 179–187.

You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer cell. 2012; 22(1): 9–20.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391): 1145–1147.

Van Speybroeck L. From epigenesis to epigenetics: the case of CH Waddington. Annals of the New York Academy of Sciences. 2002; 981(1): 61–81.

Přikrylová T, Pacherník J, Kozubek S, Bártová E. Epigenetics and chromatin plasticity in embryonic stem cells. World Journal of Stem Cells. 2013; 5(3): 73–85.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127): 1546–1558.

Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW. Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences. 2008; 105(11): 4283–4288.

Yatabe Y, Tavaré S, Shibata D. Investigating stem cells in human colon by using methylation patterns. Proceedings of the National Academy of Sciences. 2001; 98(19): 10839–10844.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science Translational Medicine. 2013; 5(169): 169ra10–169ra10.

Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381): 306–313.

Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4): 633–644.

Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Medicine. 2013; 19(11): 1438–1449.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5): 871–890.

Luis NM, Morey L, Di Croce L, Benitah SA. Polycomb in stem cells: PRC1 branches out. Cell Stem Cell. 2012; 11(1): 16–21.

Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature Reviews Genetics. 2007; 8(1): 9–22.

Simon JA, Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Molecular Cell. 2013; 49(5): 808–824.

Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7(3): 299–313.

Richly H, Aloia L, Di Croce L. Roles of the polycomb group proteins in stem cells and cancer. Cell Death & Disease. 2011; 2(9): p.e204.

Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301(5895): 89–92.

Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2007; 1775(1): 138–162.

Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Reviews Cancer. 2004; 4(2): 143–153.

Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bisht KS, Ho AS. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004; 6(4): 361–371.

Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4): 934–947.

Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nature Genetics. 2007; 39(3): 311–318.

Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nature Reviews Endocrinology. 2009; 5(4): 219–226.

Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes. 2008; 57(12): 3189–3198.

Zheng Q, Xu Y, Liu Y, Zhang B, Li X, Guo F, Zhao Y. Induction of Foxp3 demethylation increases regulatory CD4+ CD25+ T cells and prevents the occurrence of diabetes in mice. Journal of Molecular Medicine. 2009; 87(12): 1191–1205.

Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Human Immunology. 1986; 17(4): 456–470.

Wülfing C, Sumen C, Sjaastad MD, Wu LC, Dustin ML, Davis MM. Costimulation and endogenous MHC ligands contribute to T cell recognition. Nature Immunology. 2002; 3(1): 42–47.

Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937): 356–361.

Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto A, Shiozawa S. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis & Rheumatism. 2006; 54(3): 779–787.

Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998; 281(5381): 1305–1308.

Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. Journal of Neuroscience Research. 2007; 85(9): 2006–2016.

Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple sclerosis is developmentally immature. The Journal of Clinical Investigation. 1994; 94(1): 146–154.

Marques S, Outeiro TF. Epigenetics in Parkinson’s and Alzheimer’s diseases. In Kundu T, (eds). Epigenetics: Development and Disease. Subcellular Biochemistry. Dordrecht: Springer; 2013; 507–525.

Marques SC, Oliveira CR, Outeiro TF, Pereira CM. Alzheimer’s disease: the quest to understand complexity. Journal of Alzheimer’s Disease. 2010; 21(2): 373–383.

Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environmental and Molecular Mutagenesis. 2008; 49(1): 4–8.

Kovalchuk O. Epigenetic research sheds new light on the nature of interactions between organisms and their environment. Environmental and Molecular Mutagenesis. 2008; 49(1): 1–3.

Mack GS. Epigenetic cancer therapy makes headway. Journal of the National Cancer Institute. 2006; 98(20): 1443–1444.

Zheng Y, Thompson PR, Cebrat M, Wang L, Devlin MK, Alani RM, Cole PA. Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods in Enzymology. 2003; 376: 188–199.

Iyer NG, Özdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23(24): 4225–4331.

Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry. 2001; 276(39): 36734–36741.




DOI: https://doi.org/10.37591/rrjoi.v11i1.2444

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Research & Reviews: A Journal of Immunology